Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 18/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | GALR3 | O60755 | 1/20 | 0.58 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.58 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26031830 | 0.85 | ADK (0.73) | ADKNPC1GALR3S1PR4ALDH1A1 | |
| Sangivamycin SCHEMBL29639760 | 0.84 | NPC1 (0.82) | ADKNPC1GALR3S1PR4ALDH1A1 | |
| Sangivamycin SCHEMBL14227089 | 0.84 | NPC1 (0.82) | ADKNPC1GALR3S1PR4ALDH1A1 | |
| Sangivamycin SCHEMBL10262607 | 0.84 | NPC1 (0.82) | ADKNPC1GALR3S1PR4ALDH1A1 | |
| Sangivamycin SCHEMBL15107357 | 0.84 | NPC1 (0.82) | ADKNPC1GALR3S1PR4ALDH1A1 | |
| Sangivamycin SCHEMBL12284269 | 0.84 | NPC1 (0.82) | ADKNPC1GALR3S1PR4ALDH1A1 | |
| Sangivamycin SCHEMBL2786660 | 0.84 | NPC1 (0.82) | ADKNPC1GALR3S1PR4ALDH1A1 | |
| Sangivamycin SCHEMBL13065171 | 0.84 | NPC1 (0.82) | ADKNPC1GALR3S1PR4ALDH1A1 | |
| Sangivamycin SCHEMBL195540 | 0.84 | NPC1 (0.82) | ADKNPC1GALR3S1PR4ALDH1A1 | |
| Sangivamycin SCHEMBL29897938 | 0.84 | NPC1 (0.82) | ADKNPC1GALR3S1PR4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203063-A1 | Proteasome pathway inhibitors and related methods | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203063-A1 | Proteasome pathway inhibitors and related methods | PSME1, PSMC5, PSMB1 | ADK 3161/4885NPC1 2879/4885GALR3 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.